Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 276Neoplasms 255Prostatic Neoplasms 216Colorectal Neoplasms 196Lung Neoplasms 153Multiple Myeloma 148Neoplasm Metastasis 135Ovarian Neoplasms 126Leukemia, Myeloid, Acute 123Pancreatic Neoplasms 116Melanoma 102Squamous Cell Carcinoma of Head and Neck 97Recurrence 85Endometrial Neoplasms 82Carcinoma, Renal Cell 80Glioblastoma 78Lymphoma, Non-Hodgkin 77Stomach Neoplasms 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Lymphoma 72Carcinoma, Hepatocellular 72Glioma 65Brain Neoplasms 65Uterine Cervical Neoplasms 63Sarcoma 63Head and Neck Neoplasms 63Triple Negative Breast Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 58Urinary Bladder Neoplasms 55

Interventions

Rifaximin 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Paraproteinemias × 30 days × Clear all
NCT07624760 2026-06-03

MGUS-PET

University of Zurich

Phase NA Not yet recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡